Erik Kupperman

1.5k citations

17 papers · 1.2k indexed · h-index 12

Impact in

Hematology top 5%
- Multiple Myeloma Research and Treatments
Cell Biology top 5%

Papers in

Genetics 4
- Chronic Lymphocytic Leukemia Research 3
Hematology 4
- Multiple Myeloma Research and Treatments 3
- Acute Myeloid Leukemia Research 1

Co-authors: Didier Y. R. Stainier Songzhu An Nicholas J. Osborne Judy L. Meinkoth Wen Wei Bret Bannerman Yueying Cao Li Yu
Journals: Molecular Cancer Therapeutics (3 papers)Journal of Biological Chemistry (2 papers)Cancer Research (2 papers)Blood (2 papers)Clinical and Translational Science (1 paper)
Partner nations: United States Japan Netherlands

In The Last Decade

Erik Kupperman

17 papers receiving 1.1k citations

Peers

Countries citing papers authored by Erik Kupperman

Since Specialization

Citations

This map shows the geographic impact of Erik Kupperman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erik Kupperman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erik Kupperman more than expected).

Fields of papers citing papers by Erik Kupperman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erik Kupperman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erik Kupperman. The network helps show where Erik Kupperman may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Erik Kupperman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Erik Kupperman Line = papers co-authored together Erik Kupperman links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work
1	Efficacy and safety of eculizumab in Guillain‐Barré syndrome: A phase 3, multicenter, double‐blind, randomized, placebo‐controlled clinical trial Journal of the Peripheral Nervous System ·Satoshi Kuwabara, Susumu Kusunoki, Motoi Kuwahara, Yoshihisa Yamano, Yoichiro Nishida, Lajos Duró, Patricia Poblete, Erik Kupperman, Qun Lin, Glen Frick, Sonoko Misawa	2024	9
2	Efficacy and Safety of Ravulizumab, a Complement C5 Inhibitor, in Adults With Amyotrophic Lateral Sclerosis JAMA Neurology ·Angela Genge, Leonard H. van den Berg, Glen Frick, Steve Han, Sarwin L. Bauka, Adam Simmons, Qun Lin, Kaushik Patra, Erik Kupperman, James D. Berry	2023	11
3	Asia‐inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial Clinical and Translational Science ·Xiaofei Zhou, Sharon Friedlander, Erik Kupperman, Farhad Sedarati, Shingo Kuroda, Zhaowei Hua, IGOR V. SHUBIN, Yuka Yamamoto, Douglas V. Faller, Douglas Bracho, Katsuhiko Nakai, Hilderline Câmara de Oliveira, Yi Dai, Karthik Venkatakrishnan	2021	13
4	TAK-960, a Novel, Orally Available, Selective Inhibitor of Polo-Like Kinase 1, Shows Broad-spectrum Preclinical Antitumor Activity in Multiple Dosing Regimens Molecular Cancer Therapeutics ·K. Tomura, Kohei Honda, Concha Marín-Barnuevo Fabo, Hitoshi Miyashita, Ю А Ильин, Saomi Murai, Noriko Uchiyama, Maki Hasegawa, Tomohiro Kawamoto, Takashi Sato, Takashi Ichikawa, Khairunnisa’ Harun, Zhe Nie, Anne Fransas, Johnny Yang, Keisuke Kuida, Erik Kupperman	2011	64
5	Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea Cancer Chemotherapy and Pharmacology ·Bret Bannerman, Ling Xu, Matthew D. Jones, Christopher Tsu, Jie Yu, Paul Hales, Johan Monbaliu, Paul Fleming, Lawrence R. Dick, Mark Manfredi, Christopher F. Claiborne, Joseph B. Bolen, Erik Kupperman, Allison Berger	2011	32
6	Abstract A207: Discovery of molecular mechanisms underlying cellular sensitivity to the PLK1 inhibitor TAK-960. Molecular Cancer Therapeutics ·Kohei Honda, Ю А Ильин, Koki Hikami, Hitoshi Miyashita, Yusuke Nakayama, Koji Yamamoto, Hisashi Anayama, K. Tomura, Keisuke Kuida, Erik Kupperman	2011	1
7	Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer Cancer Research ·Erik Kupperman, Edmund C. Lee, Yueying Cao, Bret Bannerman, Michael Fitzgerald, Allison Berger, Jie Yu, Yang Yu, Paul Hales, Frank J. Bruzzese, Jane Liu, Jonathan L. Blank, Khristofer Garcia, Christopher Tsu, Lawrence R. Dick, Paul Fleming, Li Yu, Mark Manfredi, Mark Rolfe, Joe Bolen	2010	409
8	Abstract #2921: Pharmacokinetics and pharmacodynamics of a selective proteasome inhibitor MLN9708 in nonclinical species following either intravenous or oral administration Cancer Research ·Yu Li, Alex Bulychev, Lisa M. O’Brien, Ellen F. Fries, Shaoxia Yu, Martin Paton, نظام جمشیدی, Bret Bannerman, Erik Kupperman	2009	4
9	Antitumor Activity of MLN9708, a Second-Generation Proteasome Inhibitor, in Preclinical Models of Lymphoma. Blood ·Jill Donelan, Bret Bannerman, Leah Griffiths, C. P . Dube, Paul Hales, Bradley Stringer, Kristine Burke, Hadi Danaee, Jingjing Song, Erik Koenig, G Paoloni, Erik Kupperman	2009	1
10	The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models Molecular Cancer Therapeutics ·Mark J. Williamson, Matthew D. Silva, Sara Swanson, Robbie Robertson, Li Yu, Cindy Q. Xia, Panos Hatsis, Bret Bannerman, C. P . Dube, Yueying Cao, Erik Kupperman	2009	45
11	In-Vitro and in-Vivo Evaluation of the Orally Active Proteasome Inhibitor MLN9708 in Hematological Models of Human Cancer. Blood ·Erik Kupperman, Edmund Lee, Yueying Cao, Bret Bannerman, Michael Fitzgerald, Allison Berger, Jie Yu, Julie Zhang, Paul Hales, Frank J. Bruzzese, Jane Liu, Jonathan L. Blank, Khristofer Garcia, Christopher Tsu, Lawrence R. Dick, Paul Fleming, Li Yu, Mark Manfredi, Mark Rolfe, Joseph B. Bolen	2009	1
12	A sphingosine-1-phosphate receptor regulates cell migration during vertebrate heart development Nature ·Erik Kupperman, Songzhu An, Nicholas J. Osborne, Y. Felus, Didier Y. R. Stainier	2000	329
13	Cyclic AMP activates Ras Oncogene ·Oxana M. Tsygankova, Erik Kupperman, Wen Wei, Judy L. Meinkoth	2000	58
14	RalGDS Functions in Ras- and cAMP-mediated Growth Stimulation Journal of Biological Chemistry ·Thushari Dissanayaka, Sally A. Prigent, Erik Kupperman, Lise Rioux, Sang‐Ho Park, James R. Feramisco, Michael A. White, J. Lynn Rutkowski, Judy L. Meinkoth	1997	68
15	Ras inhibits thyroglobulin expression but not cyclic adenosine monophosphate-mediated signaling in Wistar rat thyrocytes. Endocrinology ·Erik Kupperman, Ronak M. Abdullah, Wen Wei, Judy L. Meinkoth	1996	34
16	Agonist-selective regulation of polyphosphoinositide metabolism in pulmonary artery smooth muscle cells. Journal of Biological Chemistry ·Donald Button, Abraham Rothman, Philippe Chevallier-Queyron, Erik Kupperman, Branden S. Wolner, Palmer Taylor	1994	11
17	Inhibition of Thyrotropin-Stimulated DNA Synthesis by Microinjection of Inhibitors of Cellular Ras and Cyclic AMP-Dependent Protein Kinase Molecular and Cellular Biology ·Erik Kupperman, Wen Wei, Judy L. Meinkoth	1993	63

About Erik Kupperman

Erik Kupperman is a scholar working on Genetics, Hematology, Cancer Research, Cell Biology and Molecular Biology, having authored 17 papers that have together received 1.2k indexed citations. Recurring topics across this work include Protein Kinase Regulation and GTPase Signaling (4 papers), Ubiquitin and proteasome pathways (4 papers), Chronic Lymphocytic Leukemia Research (3 papers), Multiple Myeloma Research and Treatments (3 papers), Protein Degradation and Inhibitors (3 papers), Peptidase Inhibition and Analysis (2 papers), Glycosylation and Glycoproteins Research (1 paper) and Acute Myeloid Leukemia Research (1 paper). The work is most often cited by research in Hematology (211 citations), Cell Biology (251 citations), Molecular Biology (927 citations), Oncology (319 citations) and Genetics (65 citations). Erik Kupperman has collaborated with scholars based in United States, Japan and Netherlands. Frequent co-authors include Didier Y. R. Stainier, Songzhu An, Nicholas J. Osborne, Judy L. Meinkoth, Wen Wei, Bret Bannerman, Yueying Cao, Li Yu, Paul Fleming and Jie Yu. Their work appears in journals such as Molecular Cancer Therapeutics, Journal of Biological Chemistry, Cancer Research, Blood and Clinical and Translational Science.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact